Clinical Performance of the Automated LIAISON® Meridian <i>H. pylori</i> SA Stool Antigen Test

Opekun, Antone R.; Zierold, Claudia; Rode, Ashli M.; Blocki, Frank; Fiorini, Giulia; Saracino, Ilaria Maria; Vaira, Dino; Sutton, Fred M.

doi:10.1155/2020/7189519

Cited by 17 publications

(13 citation statements)

References 37 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The test was used on 277 patients for whom an endoscopy was performed. Compared to a composite reference test including histology, culture and a RUT, the LIAISON ® Meridian H pylori SAT gave a sensitivity of 95.5% and a specificity of 97.6% confirming its usefulness in detecting H pylori 37 …”

Section: Non‐invasive Testsmentioning

confidence: 83%

Review: Diagnosis ofHelicobacter pyloriinfection

2020

View full text Add to dashboard Cite

New endoscopic techniques, especially linked colour imaging (LCI) and blue laser imaging (BLI), were extensively evaluated this year either for the diagnosis of Helicobacter pylori gastritis or the detection of early gastric cancer (EGC). In the first case, the studies followed a similar protocol. Endoscopy was performed with the new imaging technique as well as white light imaging (WLI) on a group of patients for whom the H pylori status was established by various methods. Several images were obtained from different parts of the stomach and submitted blindly to a group of endoscopists (at least 4) for evaluation. The first aim was to determine the sensitivity and specificity of the new method vs WLI. LCI always performed better than WLI with sensitivity and specificity for LCI ranging from 83.8% to 85.4% and 79.5% to 99.5%, respectively (Table 1). The difficulty stemmed from the fact that there are different stages of H pylori gastritis, from active inflammation to atrophy and intestinal metaplasia, which exhibit very different aspects. Nevertheless in their study, Wang et al concluded that identification of H pylori gastritis by LCI was especially reliable in the corpus. 1 In another study by Jiang et al, using a score of 3.5 as the cutoff value, sensitivity and specificity were 83.8% and 99.5%, respectively, for the diagnosis of H pylori gastritis among 358 patients. 2 Ono et al 3

show abstract

Section: Non‐invasive Testsmentioning

confidence: 83%

Review: Diagnosis ofHelicobacter pyloriinfection

2020

View full text Add to dashboard Cite

show abstract

“…This test uses a monoclonal antibody sandwich method and chemiluminescent immunoassay technology. A sensitivity of 95.5% and a specificity of 97.6% were obtained for LIAISON, in comparison to a sensitivity and specificity exceeding 80% in previously used monoclonal antibody-based tests [ 100 ]. In a recent comparison of LIAISON ® with an ELISA test procedure (RIDASCREEN ® , R-Biopharm, Darmstadt, Germany) and an immunochromatography test from the same company (RIDAQUICK ® ), very comparable results were demonstrated for the diagnostic accuracy of the mentioned tests [ 101 ].…”

Section: Noninvasive Methodsmentioning

confidence: 95%

Diagnostic approach to Helicobacter pylori-related gastric oncogenesis

Rupp

Papaefthymiou

Chatzimichael

et al. 2022

aog

View full text Add to dashboard Cite

Helicobacter pylori ( H. pylori ) is a causative agent of peptic ulcer disease and plays an important role in the development of various other upper and lower gastrointestinal tract and systemic diseases; in addition to carcinogenesis and the development of mucosa-associated lymphoid tissue lymphoma, extragastric manifestations of H. pylori are increasingly being unraveled. Therefore, prompt and accurate diagnosis is essential. Within this narrative review we present an overview of the current trend in the diagnosis of H. pylori infection and its potential oncogenic sequelae, including gastric mucosa atrophy, intestinal metaplasia, dysplasia and gastric cancer. Signs of H. pylori -related gastric cancer risk can be assessed by endoscopy using the Kyoto classification score. New technology, such as optical or digital chromoendoscopy, improves diagnostic accuracy and provides information regarding H. pylori -related gastric preneoplastic and malignant lesions. In addition, a rapid urease test or histological examination should be performed, as these offer a high diagnostic sensitivity; both are also useful for the diagnosis of sequelae including gastric and colon neoplasms. Culture is necessary for resistance testing and detecting H. pylori -related gastric dysbiosis involved in gastric oncogenesis. Likewise, molecular methods can be utilized for resistance testing and detecting H. pylori -related gastric cancer development and progression. Noninvasive tests, such as the urea breath and stool antigen tests, can also be implemented; these are also suitable for monitoring eradication success and possibly for detecting H. pylori -related gastric malignancy. Serological tests may help to exclude infection in specific populations and detect gastric and colon cancers. Finally, there are emerging potential diagnostic biomarkers for H. pylori -related gastric cancer.

show abstract

“…Eradication of H. pylori was defined by a negative stool antigen test, according to standard clinical practice in our center, performed 4–8 weeks after the end of retreatment. The test used was “LIAISON ® Meridian H. pylori SA”, a chemiluminescent immunoassay (CLIA) stool antigen test, which applies monoclonal antibodies (DiaSorin Iberia S.A., Madrid, Spain) [ 35 ].…”

Section: Methodsmentioning

confidence: 99%

Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection

Resina

Gisbert

2021

Antibiotics

View full text Add to dashboard Cite

Helicobacter pylori infection may persist after multiple eradication treatments. The aim of this study was to evaluate the efficacy and safety of a furazolidone-based rescue regimen in hyper-refractory patients. A unicentre, prospective study was designed. Patients in whom five or more treatments had consecutively failed were included. All patients had previously received bismuth and key antibiotics, such as amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and rifabutin, and had positive H. pylori culture, demonstrating resistance to clarithromycin, metronidazole, and levofloxacin. A quadruple regimen with furazolidone (200 mg), amoxicillin (1 g), bismuth (240 mg), and esomeprazole (40 mg) was prescribed twice a day for 14 days. Eradication was confirmed by the stool antigen test. Compliance was determined through questioning, and adverse effects using a questionnaire. Eight patients (mean age 56 years, 63% men, 38% peptic ulcer disease, 12% gastric cancer precursor lesions, and 50% functional dyspepsia) were included. Per-protocol and intention-to-treat eradication rates were 63%. Compliance was 100%. Adverse effects were reported in two (25%) patients, and all were mild. Even after five or more previous H. pylori eradication failures, and a multi-resistant infection, rescue treatment with furazolidone may be effective in approximately two-thirds of the cases, constituting a valid strategy after multiple previous eradication failures with key antibiotics such as clarithromycin, metronidazole, tetracycline, levofloxacin, and rifabutin.

show abstract

Clinical Performance of the Automated LIAISON® Meridian H. pylori SA Stool Antigen Test

Cited by 17 publications

References 37 publications

Review: Diagnosis ofHelicobacter pyloriinfection

Review: Diagnosis ofHelicobacter pyloriinfection

Diagnostic approach to Helicobacter pylori-related gastric oncogenesis

Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection

Contact Info

Product

Resources

About